Gateways to clinical trials: January/February 2007

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 29, Issue 1, 2007, Pages 53-71

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ARGININE; ATRASENTAN; AZIMILIDE; CERTOLIZUMAB PEGOL; CHIR 258; CILANSETRON; CLOPIDOGREL; CYSTEMUSTINE; DELAPRIL; ETRAVIRINE; FENRETINIDE; HUMAN INSULIN; HYALURONIC ACID; HYDROCHLOROTHIAZIDE; LOSARTAN; MANIDIPINE; MARAVIROC; METFORMIN; NIBENTAN; OLMESARTAN; PEXELIZUMAB; PLACEBO; PRASUGREL; RC 3095; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOLVAPTAN; UNINDEXED DRUG; VILDAGLIPTIN; VINFLUNINE;

ANGINA PECTORIS; ARTICLE; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROHN DISEASE; DRUG POTENTIATION; GLIOMA; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; IRRITABLE COLON; KIDNEY CARCINOMA; LEUKOPLAKIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; HUMANS;

EID: 33947365129     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (115)

1. Losordo, D.W., Kearney, M., Patel, S. et al. Randomized, double blind, placebo controlled pilot trial of intramyocardial autologous CD34 cell therapy for intractable angina. Circulation 2006, 114(18, Suppl. 2): Abst 3361.
2. Serebruany, V., Midei, M., Meilman, H., Malinin, A., Lowry, D. Platelet inhibition with prasugrel (CS-747) versus clopidogrel in patients undergoing coronary stenting (JUMBO platelet substudy). Atherosclerosis Suppl 2006, 7(3): Abst We-P11: 212.
3. Shoaf, S.E. et al. Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias. J Cardiovasc Pharmacol Ther 2005, 10(3): 165.
4. Diaz, A.V.H., Westerhout, C.M., Steyerberg, E.W. et al. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST-segment elevation acute coronary syndromes: Benefit and harm in different age subgroups. Eur Heart J 2006, 27(Abstract Suppl.): Abst P4559.
5. Koifman, B., Topilski, I., Megidish, R. et al. Effects of losartan + L-arginine on nitric oxide production, endothelial cell function, and hemodynamic variables in patients with heart failure secondary to coronary heart disease. Am J Cardiol 2006, 98(2): 172.
6. Armstrong, P.W., Mahaffey, K.W., Chang, W.C. et al. Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. Am Heart J 2006, 151(4): 787.
7. Hudson, M.P., Armstrong, P.W., Ruzyllo, W. et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: Results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006, 48(1): 15.
8. Kerr, C.R., Connolly, S.J., Kowey, P. et al. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol 2006, 98(2): 215.
9. Bregvadze, I.N. et al. The efficacy and safety of new class III antiarrhythmic drug nibentan for cardioversion in patients with persistent atrial fibrillation. Eur Heart J 2006, 27(Abstract Suppl.): Abst P5162.
10. Preti, P., Destro, M., Lazzari, P. et al. Efficacy and tolerability of delapril-manidipine combination vs olmesartan-hydrochlorothiazide fixed combinations in elderly diabetic hypertensive patients. J Clin Hypertens (Greenwich) 2006, 8(5, Suppl. A): Abst P-219.
11. Wallny, T., Palmedo, H., Brackmann, H., Hess, L., Oldenburg, J. Rhenium-186 hydroxyethylidenediphosphonate (186Re-HEDP): A novel treatment for haemophilic arthropathies? Haemophilia 2006, 12(Suppl. 2): Abst 18 PO 579.
12. Abshire, T., Hoots, K., Kessler, C., MacFarlane, D., Bergman, G. Preclinical and clinical experiences with a recombinant porcine FVIII product. Haemophilia 2006, 12(Suppl. 2): Abst 20 S 644.
13. Provelengios, S., Vergados, N., Loukopoulou, E., Kouraba, A., Balomenou, A., Karafoulidou, A. Intra-articular injection of hyaluronic acid for the treatment of haemophilic arthropathy. Haemophilia 2006, 12(Suppl. 2): Abst 18 PO566.
14. Sandborn, W.J. et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: Results from a 26-week, placebo-controlled phase III study (PRECiSE 1). Gastroenterology 2006, 130(4, Suppl. 2): Abst 745.
15. Buchman, L.A., Katz, S., Shnaidman, M., Jacobs, D. Effect of teduglutide in patients with moderate-severe Crohn's disease after 20 weeks of daily therapy. Am J Gastroenterol 2006, 101 (Suppl. 2): Abst 1190.
16. Castell, O.D., Macg., Hirota, K.W. et al. XP19986 decreases reflux and is well tolerated in GERD patients. Am J Gastroenterol 2006, 101(Suppl. 2): Abst 52.
17. Francisconi, C.F., Drossman, D.A., Mayer, E.A., Caras, S. Interruption of daily activities in cilansetron-treated patients with irritable bowel syndrome with diarrhea predominance (IBS-D): Results from a 16-week, placebo-controlled, rerandomization trial. Gastroenterology 2006, 130(4, Suppl. 2): Abst T2042.
18. Chiesa, F. et al. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: Long-term results. Int J Cancer 2005, 115(4): 625.
19. Cohen, L.B., Wang, C., Jones, J.B. Aquavan is safe and effective for minimal to moderate sedation during colonoscopy. Anesthesiology 2006, 105(Suppl.): Abst A1367.
20. Dezube, B.J., Krown, S.E., Lee, J.Y., Bauer, K.S., Aboulafia, D.M. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS Malignancy Consortium Study. J Clin Oncol 2006, 24(9): 1389.
21. Cahn, P., Cassetti, I., Wood, R. et al. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 2006, 20(9): 1261.
22. Vingerhoets, J., Janssen, K., Welkenhuysen-Gybels, J. et al. Impact of baseline K103N or Y18IC on the virological response to the NNRTI TMC125: Analysis of study TMC125-C223. Antivir Ther 2006, 11(5, Suppl.): S22.
23. Rosario, M.C., Poland, B., Sullivan, J., Westby, M., van der Ryst, E. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. J Acquir Immune Defic Syndr (JAIDS) 2006, 42(2): 183.
24. Abs, R., Didier, E., Boonen, A., Kantaridis, C., Weissgerber, G., Harris, P. The pharmacokinetics, pharmacodynamics and safety of pegylated recombinant human growth hormone after single subcutaneous injections in adult male patients with growth hormone deficiency. Horm Res 2006, 65(Suppl. 4): Abst PO1-517.
25. Sindrup, S.H., Graf, A., Sfikas, N. The NK(1)-receptor antagonist TKA731 in painful diabetic neuropathy: A randomised, controlled trial. Eur J Pain 2006, 10(6): 567.
26. Teeter, J.G., Riese, R.J. Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. Am J Respir Crit Care Med 2006, 173(11): 1194.
27. Ahren, B., Pacini, G., Foley, J.E. et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005, 28(8): 1936.
28. Castaño, G., Mas, R., Fernandez, L. et al. A comparison of the effects of D-003 and policosanol (5 and 10 mg/d) in patients with type II hypercholesterolemia: A randomized, double-blinded study. Atherosclerosis Suppl 2006, 7(3): Abst Th-P16, 325.
29. Goss, G., Siu, L.L., Gauthier, I. et al. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND. 147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Cancer Chemother Pharmacol 2006, 58(5): 703.
30. Sarantopoulos, J. et al. Banoxantrone (AQ4N), tissue CYP 450 targeted prodrug: The results of a phase I study using an accelerated dose escalation. J Clin Oncol 2006, 24(18, Suppl.): Abst 2011.
31. Lee, C.P. et al. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). J Clin Oncol 2006, 24(18, Suppl.): Abst 3015.
32. Sarker, D. et al. A phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of CHIR-258, a novel oral multiple receptor tyrosine kinase (RTK) inhibitor. J Clin Oncol 2006, 24(18, Suppl.): Abst 3043.
33. D'Adamo, D.R., Scheu, K., Singer, S., Schwartz, G.K., Maki, R.G. A phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma. J Clin Oncol 2006, 24(18, Suppl.): Abst 9523.
34. Mita, C.A. et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of MDX-214, a novel immune-mediated mechanism agent targeting the epithelial growth factor receptor (EGFR), in patients with advanced solid tumors. J Clin Oncol 2006, 24(18, Suppl.): Abst 2523.
35. Kato, K. et al. Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle, in patients with advanced cancer. J Clin Oncol 2006, 24(18, Suppl.): Abst 2018.
36. Daud, A. et al. Phase I trial of CT-2106 (polyglutamated camptothecin) administered weekly in patients (pts) with advanced solid tumors. J Clin Oncol 2006, 24(18, Suppl.): Abst 2015.
37. Schwartsmann, G., Dileone, L.P., Horowitz, M. et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest New Drugs 2006, 24(5): 403.
38. Camacho, L.H. et al. Phase-1 trial of ZIO-101, a novel organic arsenic in patients with advanced cancers. J Clin Oncol 2006, 24(18, Suppl.): Abst 13041.
39. Zuehlsdorf, M. et al. VEGF, sVEGFR-2, bFGF, and IL-8 as biomarkers of the pharmacological activity of BAY 57-9352, an oral VEGFR-2 receptor tyrosine kinase inhibitor, in patients with solid tumors. J Clin Oncol 2006, 24(18, Suppl.): Abst 3035.
40. Warren, K., Jakacki, R., Widemann, B. et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: A report from the Children's Oncology Group. Cancer Chemother Pharmacol 2006, 58(3): 343.
41. Garrison, L.P., Jr., Perez, E.A., Dueck, A., Lalla, D., Paton, V., Lubeck, D. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2 positive breast cancer. J Clin Oncol 2006, 24(18, Suppl.): Abst 6023.
42. Veronesi, U., Mariani, L., Decensi, A. et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006, 17(7): 1065.
43. Safran, H. et al. GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, phase I study for advanced pancreaticobiliary cancer. J Clin Oncol 2006, 24(18, Suppl.): Abst 4002.
44. Ramanathan, R.K. et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J Clin Oncol 2006, 24(18, Suppl.): Abst 4010.
45. Durando, X., Thivat, E., Roché, H. et al. Cystemustine in recurrent high grade glioma. J Neuro-Oncol 2006, 79(1): 33.
46. Lin, N.U. et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol 2006, 24(18, Suppl.): Abst 503.
47. Correale, P., Remondo, C., Montagnani, F. et al. Chemoimmunotherapy regimen with gemcitabine plus FOLFOX 4 (GOLF) followed by subcutaneous(Sc) granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2): Results from a multicenter phase II trial in colon carcinoma patients. J Clin Oncol 2006, 24(18, Suppl.): Abst 3587.
48. Reid, T., Spears, C., Subramanian, M. et al. Response to second line treatment following 5,10-methylenetetrahydrofolic acid with 5-fluorouracil as first line treatment in metastatic colorectal cancer. Ann Oncol 2006, 17(Suppl. 6): Abst P-186.
49. Luftner, D., Siepmann, S., Christian, J. et al. Randomized, phase III trial comparing liposomal platin with cisplatin in patients (pts) with advanced squamous cell carcinoma of the head and neck(SCCHN) regarding safety and efficacy profiles. J Clin Oncol 2006, 24(18, Suppl.): Abst 5564.
50. Gajewski, T.F., Niedzwiecki, D., Johnson, J. et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104. J Clin Oncol 2006, 24(18, Suppl.): Abst 8014.
51. Barrio, M.M. et al. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother 2006, 29(4): 444.
52. Ricart, A.D., Papadopoulos, K.P., Von Hoff, D.D., Lim, J.K.C., Marschke, R.F. A phase I and pharmacokinetic (PK) study of CX-3543, a protein-rDNA quadruplex inhibitor, in patients (pts) with advanced solid tumors. Eur J Cancer Suppl 2006, 4(12): Abst 358.
53. Mita, A.C., Antonia, S., Lewis, L.D. et al. Final safety, pharmacokinetic and antitumor activity results of a phase I study of YM155, a novel survivin inhibitor, when administered by 168 hour continuous infusion. Eur J Cancer Suppl 2006, 4(12): Abst 29LB1.
54. Ravaud, A. et al. Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 2006, 24(18, Suppl.): Abst 4502.
55. Goldstein, D., Ackland, S.P., Bell, D.R. et al. Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Invest New Drugs 2006, 24(5): 429.
56. Giles, F.J., Larson, R., Le Coutre, P. et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). J Clin Oncol 2006, 24(18, Suppl.): Abst 6536.
57. Ottmann, O., Bhalla, K., Kantarjian, H. et al. Bcr-Abl mutations in imatinib-resistant CML and Ph+ALL patients (pts) enrolled in a phase I study of AMN107. J Clin Oncol 2006, 24(18, Suppl.): Abst 6527.
58. Blum, W., Klisovic, R.B., Kefauver, C. et al. Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics. J Clin Oncol 2006, 24(18, Suppl.): Abst 6568.
59. Grosso, F. et al. Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. J Clin Oncol 2006, 24(18, Suppl.): Abst 9511.
60. Crowley, J., Furuse, K., Kawahara, M. et al. Second Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenomics. J Clin Oncol 2006, 24(18, Suppl.): Abst 7050.
61. Piekarz, R.L., Frye, A.R., Wright, J.J. et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006, 12(12): 3762.
62. Kulke, M.H., Bergsland, E.K., Ryan, D.P. et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006, 24(22): 3555.
63. Nicodemus, C.F., Berek, J.S., Schultes, B.C., Balser, J.P., Taylor, P.T. Final follow up survey of the randomized Pbo-controlled study of oregovomab (Ov) as a consolidation treatment for advanced ovarian cancer (OC): Insights into surveillance approaches. J Clin Oncol 2006, 24(18, Suppl.): Abst 5079.
64. Nelson, J.B., Sleep, D.J., Isaacson, J.D., Carducci, M.A. Limitation of prostate-specific antigen doubling time as a predictor of outcome in hormone-naive prostate cancer. J Clin Oncol 2006, 24(18, Suppl.): Abst 4566.
65. Doroshow, J.H., McCoy, S., Macdonald, J.S. et al. Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study. Invest New Drugs 2006, 24(6): 537.
66. Schuster, M.W., Anaissie, E., Hurd, D. et al. Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single dose velafermin (CG53135-05) for the prevention of oral mucositis. J Clin Oncol 2006, 24(18, Suppl.): Abst 6537.
67. Kornblau, S.M. et al. A phase 1 trial of a novel organic arsenic S-dimethylarsino-glutathione (ZIO-101) in hematological malignancies. J Clin Oncol 2006, 24(18, Suppl.): Abst 16503.
68. Roboz, G.J., Giles, F.J., List, A.F. et al. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2006, 20(6): 952.
69. Koziner, B., O'Brien, S., Boyd, T., Larratt, L., Moore, J., Chanan-Khan, A. Pooled safety analysis of oblimersen alone or with fludarabine and cyclophosphamide in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2006, 24(18, Suppl.): Abst 6611.
70. Kantarjian, H.M., Gattermann, N., O'Brien, S.G. et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP). J Clin Oncol 2006, 24(18, Suppl.): Abst 6534.
71. Kreitman, R.J., Wilson, W.H., Stetler-Stevenson, M., Fitzgerald, D.J., Pastan, I. Complete remissions to anti-CD22 immunotoxin BL22 in phase I and II trials of patients with chemoresistant hairy cell leukemia may be monitored by assays for soluble CD22 and CD25. Proc Am Assoc Cancer Res (AACR) 2006, 47: Abst 5652.
72. Forero-Torres, A. et al. A humanized antibody against CD40(SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study. J Clin Oncol 2006, 24(18, Suppl.): Abst 7534.
73. Lundahl, J. et al. Spectral profiles during NREM sleep for gaboxadol and Zolpidem in the treatment of patients with primary insomnia. Sleep 2006, 29(Abst): Abst 0718.
74. Dunbar, G.C., Kuchibhatla, R., Wamsley, J.K. Evidence of efficacy for TC-1734 (AZD3480) in the treatment of cognitive impairment in older subjects. Eur Neuropsychopharmacol 2006, 16(Suppl.4): S547.
75. Schmouder, R., Aradhye, S., O'Connor, P., Kappos, L. et al. Pharmacodynamic effects of oral fingolimod (FTY720). Multiple Scler 2006, 12(1, Suppl.): Abst P378.
76. Kappos, L., Antel, J., Comi, G., Montalban, X. et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: 24-Month results of the phase II study. Multiple Scler 2006, 12(1, Suppl.): Abst P376.
77. Kranz, M., Warren, K., Catz, I., Ferenci, L. Treatment of multiple sclerosis by antigen specific tolerance induction with synthetic peptide MBP8298: Hla-Dr specific delay of disease progression in a phase II clinical study. Clin Immunol 2006, 119 (Suppl. 1): Abst OR.112.
78. Rog, D.J., Nurmikko, T.J., Sarantis, N.S., Young, C.A. A long-term open-label trial of safety and efficacy of Sativex, a cannabis based medicine, in central neuropathic pain due to multiple sclerosis. J Neurol 2006, 253(Suppl. 2): Abst P395.
79. Fernandez, H.H. Istradefylline for the treatment of motor response complications on levodopa in PD patients: Results of the KW-6002-US-018 study focusing on functional and motor improvement. Mov Disord 2006, 21 (Suppl. 15): Abst P1136.
80. Guttman, M. Efficacy of istradefylline in Parkinson's disease patients treated with levodopa with motor response complications: Results of the KW-6002-US-018 study. Mov Disord 2006, 21(Suppl. 15): Abst P934.
81. Pourcher, E. Safety and tolerability of istradefylline (KW-6002) in Parkinson's disease with motor response. Mov Disord 2006, 21(Suppl. 15): Abst P664.
82. Hauser, R.A. Efficacy of istradefylline (KW-6002) in levodopa-treated Parkinson's disease patients with motor response complications: Secondary efficacy results of the KW-6002-US-013 study. Mov Disord 2006, 21 (Suppl. 15): Abst P673.
83. Trugman, J.M. Efficacy of istradefylline (KW-6002) in levodopa-treated Parkinson's disease patients with motor response complications: Primary efficacy results of the KW-6002-US-013 Study. Mov Disord 2006, 21(Suppl. 15): Abst P682.
84. Shulman, L.M. The safety profile of istradefylline (KW-6002) in Parkinson's disease with motor response complications on levodopa/carbidopa: Results of KW-6002 US-013 study. Mov Disord 2006, 21 (Suppl. 15): Abst P591.
85. Rascol, O., Lees, A.J., Poewe, W., Salin, L. NS 2330, a DA reuptake inhibitor, in levodopa-treated patients with Parkinson's disease and motor fluctuations: The phase II ADVANS study. Mov Disord 2006, 21 (Suppl. 15): Abst P690.
86. Roth, T., White, D., Schmidt-Nowara, W. et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: A 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006, 28(5): 689.
87. Wilens, T.E., Verlinden, M.H., Adler, L.A., Wozniak, P.J., West, S.A. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: Results of a pilot study. Biol Psychiatry 2006, 59(11): 1065.
88. Olincy, A., Harris, J.G., Johnson, L.L. et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006, 63(6): 630.
89. Lane, H.-Y., Huang, C.-L., Wu, P.-L. et al. Glycine transporter I inhibitor. N-methylglycine (Sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006, 60(6): 645.
90. Gambacciani, M., Cappagli, B., Lazzarini, V., Ciaponi, M., Fruzzetti, F., Genazzani, A.R. Longitudinal evaluation of perimenopausal bone loss: Effects of different low dose oral contraceptive preparations on bone mineral density. Maturitas 2006, 54(2): 176.
91. Boot, J.D., Tarasevych, S., Wang, L. et al. Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on allergen-induced airway responses and inflammation in asthma. Proc Am Thorac Soc 2006, 3(Abstracts Issue): A80.
92. Pearlman, D., Greos, L., LaForce, C., Orevillo, C., Armstrong, G., Higgins, M. Indacaterol, a novel once-daily beta2-agonist, provides full 24-hour bronchodilatory efficacy in patients with persistent asthma. Proc Am Thorac Soc 2006, 3(Abstracts Issue): A79.
93. LaForce, C., Aisanov, Z., Higgins, M., Cameron, R., Owen, R. Indacaterol, a novel once-daily betal-agonist demonstrates efficacy and safety in patients with persistent asthma: A 7-day, multiple-dose study. Proc Am Thorac Soc 2006, 3(Abstracts Issue): A79.
94. Singh, D., Corris, P.A., Snape, S. NVA237, a once-daily inhaled anti-muscarinic, provides 24-hour bronchodilator efficacy with comparable bronchodilation to albuterol in patients with moderate-to-severe COPD. Proc Am Thorac Soc 2006, 3(Abstracts Issue): A113.
95. Calverley, P.M., Sanchez-Toril, F., McIvor, R.A., Teichmann, P., Bredenbroeker, D., Fabbri, L.M. Effect of roflumilast on lung function: A 1-year study in patients with severe to very severe COPD. Proc Am Thorac Soc 2006, 3(Abstracts Issue): A725.
96. Grasemann, H., Kurtz, F., Ratjen, F. Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med 2006, 174(2): 208.
97. Waltz, D.A., Treseler, J., Deboeck, A., King, M. A phase Ia, randomized, placebo-controlled, double blind safety and tolerability study of multiple ascending inhaled doses of NACYSTE-LYN in patients with cystic fibrosis. Proc Am Thorac Soc 2006, 3 (Abstracts Issue): A410.
98. Wikström, B., Gellert, R., Ladefoged, S.D. et al. kappa-Opioid system in uremic pruritus: Multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005, 16(12): 3742.
99. Peng, X., Yan, H., You, Z., Wang, P., Wang, S. Glutamine granule-supplemented enteral nutrition maintains immunological function in severely burned patients. Burns 2006, 32(5): 589.
100. Gibiansky, E., Gibiansky, L. Optimization of Aquavan injection dosing for sedation: Excellent prediction of sedation outcomes. Anesthesiology 2006, 105(Suppl.): Abst A1204.
101. Agnelli, G. et al. A phase II study of the safety and efficacy of a novel oral FXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR or THR. Blood 2005, 106(11): Abst 278.
102. Stead, R.B., Lambert, J., Wessels, D. et al. Evaluation of the safety and pharmacodynamics of Hematide[TM], a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose escalation study in healthy volunteers. Blood 2006, 108(6): 1830.
103. Lin, J., Zhang, J., Dong, X. et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: A phase I randomised controlled trial. Lancet 2006, 368(9540): 991.
104. Lobo, B., Serra, J., Azpiroz, F., D'Amato, M., Malagelada, J.R. Dexloxiglumide, a CCK1-antagonist, improves gas-related symptoms in healthy subjects. Gastroenterology 2006, 130(4, Suppl. 2): Abst T2030.
105. Rad, M., Kluft, C., Ménard, J. et al. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. Am J Obstet Gynecol 2006, 195(1): 72.
106. McMahon, J.A., Green, T.J., Skeaff, C.M., Knight, R.G., Mann, J.I., Williams, S.M. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006, 354(26): 2764.
107. Lund, J. et al. Gaboxadol has little or no effect on cognitive and psychomotor tests compared to zolpidem, and the two compounds have limited potential for interaction in healthy subjects. Sleep 2006, 29(Abst.): Abst 0124.
108. Johnston, J., Bryant, A.P., Busby, R.W. et al. Early clinical characterization of MD-0727, a novel cholesterol absorption inhibitor, in healthy subjects. Atherosclerosis Suppl 2006, 7(3): Abst Th-P16: 297.
109. Barnetson, R.S., Ooi, T.K., Zhuang, L. et al. [Nle(4)-D-Phe(7)]-alpha- melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006, 126(8): 1869.
110. Avijgan, M., Moghni, M., Ialehgani, F. Immunogenicity and reactogenicity after MMR vaccination to mumps part of vaccine in seronegative persons. Int J Infect Dis 2006, 10(Suppl. 1): Abst 1SE.398.
111. Hermann, R., Lahu, G., Huennemeyer, A., Knoerzer, D., Wurst, W., Haverkamp, W. Roflumilast treatment does not alter cardiac repolarization in healthy subjects. Proc Am Thorac Soc 2006, 3 (Abstracts Issue): A112.
112. Hohlfeld, J.M., Schoenfeld, K., Lavae-Mokhtari, M. et al. Roflumilast inhibits recruitment of inflammatory cells into the lung after segmental LPS challenge in healthy subjects. Proc Am Thorac Soc 2006, 3(Abstracts Issue): A849.
113. De Mey, C., Hauns, B., Knoerzer, D. et al. Roflumilast does not potentiate tachycardia associated with formoterol. Proc Am Thorac Soc 2006, 3(Abstracts Issue): A112.
114. De Mey, C., Hauns, B., Lahu, G. et al. Repeated-dose co-administration of roflumilast and formoterol does not alter the pharmacokinetics of either drug. Proc Am Thorac Soc 2006, 3 (Abstracts Issue): A113.
115. Davidson, M.H., Smith, J., Scott, R., Small, R., Choi, J., Kane, J.P. Assessment of Lipoprotein Profiles (ALPs study) and anti-oxidant activity in healthy subjects treated with AGI-1067. Atherosclerosis Suppl 2006, 7(3): Abst Th-P16: 331.